Table II. Summary of Systematic Reviews and Meta-Analyses Assessing the Association Between Psoriasis and Cardiovascular Disease Risk Factors.

Study	Study Dates	Total Number of Patients		Number of	CV Risk	Composite Measure of Association
		Psoriasis	No Psoriasis	Studies Included	Factor	(95% CI)
Armstrong, et al. ⁷¹ 2012	January 1, 1980 - January 1, 2012	201,831	2,119,329	Total: 16 Severity Assessment: 5 Incidence: 1	Obesity	Overall: OR 1.66 (1.46-1.89) Mild: OR 1.46 (1.17-1.82) Severe: OR 2.23 (1.63-3.05) Incidence: HR 1.18 (1.14-1.23)
Armstrong, et al. ⁷³ 2012	January 1, 1980 - January 1, 2012	309,469	2,384,229	Total: 24 Severity Assessment: 5 Incidence: 2	Hypertension	Overall: OR 1.58 (1.42-1.76) Mild: OR 1.30 (1.15-1.47) Severe: OR 1.49 (1.20-1.86)

						Incidence: HR 1.09 (1.05–1.14)
						Incidence: RR 1.17 (1.06–1.30)
Armstrong, et al. ⁷⁸ 2012	January 1, 1980	404,494	4,640,847	Total: 27	Diabetes	Overall: OR 1.59 (1.38-1.83)
				Severity		Mild: OR 1.53 (1.16-2.04)
	2012			Assessment: 5		Severe: OR 1.97 (1.48-2.62)
				Incidence: 5		Incidence: RR 1.27 (1.16-1.40)
Ma, et al. ⁸¹ 2012 ^a	January 1, 1980 - January 1,	nuary 1, 265,685	2,167,198	Total: 25	Dyslipidemia	Overall OR: 1.04-5.55
				Severity Assessment: 5		Mild OR: 1.10-3.38
	2012			Incidence: 1		Severe OR: 1.26-5.55
Armstrong, et al. ⁸⁹ 2013	January 1, 1980	41,853	1,357,324	Total: 12	Metabolic Syndrome	Overall OR: 2.26 (1.70-3.01)
	- January 1, 2012			Severity		Mild OR: 1.22 (1.11-1.35) ^b

		Assessment: 3	Moderate OR: 1.56 (1.38-1.76) ^b
			Severe OR: 1.98 (1.62-2.43) ^b

828

- 829 CI, confidence interval; CV, cardiovascular; HR, hazard ratio; OR, odds ratio; RR, relative risk
- 830 ^aSystematic review only.
- bReported from single study by Langan, et al. ⁷²